| ID Source | ID |
|---|---|
| PubMed CID | 47759 |
| CHEMBL ID | 1551453 |
| CHEBI ID | 38504 |
| SCHEMBL ID | 26806 |
| MeSH ID | M0148505 |
| Synonym |
|---|
| deltanit |
| furathiocarb |
| butyl 2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl sulfanediylbis(methylcarbamate) |
| butyl 2,3-dihydro-2,2-dimethylbenzofuran-7-yl n,n-dimethyl-n,n-thiodicarbamate |
| CHEBI:38504 , |
| 2,3-dihydro-2,2-dimethyl-7-benzofuranyl 2,4-dimethyl-5-oxo-6-oxa-3-thia-2,4-diazadecanoate |
| 65907-30-4 |
| furathiocarb [bsi:iso] |
| deltanet |
| 2,3-dihydro-2,2-dimethyl-7-benzofuryl 2,4-dimethyl-6-oxa-5-oxo-3-thia-2,4-diazadecanoate |
| cga 73102 |
| benzofuran, 2,3-dihydro-2,2-dimethyl-7-(n-(n-methyl-n-butoxycarbonylaminothio)-n-methylcarbamoyloxy)- |
| einecs 265-974-3 |
| promet 660sco |
| promet |
| hsdb 6664 |
| NCGC00166193-01 |
| (2,2-dimethyl-3h-1-benzofuran-7-yl) n-[butoxycarbonyl(methyl)amino]sulfanyl-n-methylcarbamate |
| C18650 |
| 6-oxa-3-thia-2,4-diazadecanoic acid, 2,4-dimethyl-5-oxo-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester |
| benzofuran, 2,3-dihydro-2,2-dimethyl-7-(n-(n-methyl-n-butoxycarbonylaminothio)-n-methylcarbamate |
| butyl 2,3-dihydro-2,2-dimethylbenzofuran-7-yl n,n'-dimethyl-n,n'-thiodicarbamate |
| wzi2iz80uy , |
| unii-wzi2iz80uy |
| FT-0630757 |
| AKOS015902770 |
| promet-666sco |
| cga-73102 |
| furathiocarb [hsdb] |
| furathiocarb [iso] |
| SCHEMBL26806 |
| DTXSID3052725 |
| HAWJXYBZNNRMNO-UHFFFAOYSA-N |
| promet 666sco |
| CHEMBL1551453 |
| furathiocarb, pestanal(r), analytical standard |
| cga 73102; deltanet; furathiocarb; promet; promet 666sco; 6-oxa-3-thia-2,4-diazadecanoic acid, 2,4-dimethyl-5-oxo-, 2,3-dihydro-2,2-dimethyl-7-benzofuranyl ester |
| furathiocarb 100 microg/ml in acetonitrile |
| Q1474820 |
| furathiocarb 50 ug/ml in acetonitrile |
| Role | Description |
|---|---|
| EC 3.1.1.7 (acetylcholinesterase) inhibitor | An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid. |
| carbamate insecticide | Derivatives of carbamic acid with insecticidal properties of general formula ROC(=O)NR(1)R(2), where ROH is an alcohol, oxime, or phenol and R(1) is hydrogen or methyl. Like organophosphate insecticides, they are cholinesterase inhibitors, but carbamate insecticides differ in action from the organophosphates in that the inhibitory effect on cholinesterase is generally brief. |
| agrochemical | An agrochemical is a substance that is used in agriculture or horticulture. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| carbamate ester | Any ester of carbamic acid or its N-substituted derivatives. |
| 1-benzofurans | A member of the class of benzofurans consisting of a 1-benzofuran skeleton and its substituted derivatives thereof. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 3.1623 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 30.3001 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 26.6795 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (16.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||